Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 13
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 14
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 16
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 17
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 18
Partnerships 19
Mayne Pharma Enters into Distribution Agreement with IDT Australia 19
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 20
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 22
Licensing Agreements 24
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 24
HedgePath Pharma Enters Into Licensing Agreement With Mayne Pharma 25
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 27
Equity Offering 28
Mayne Pharma to Raise USD444.5 Million in Rights Offering of Shares 28
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 30
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 32
HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 33
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 34
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 35
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 36
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 37
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 39
Acquisition 40
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 40
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 41
Metrics Acquires Midlothian Labs From Hi-Tech Pharmacal 43
Mayne Pharma Group Ltd – Key Competitors 44
Mayne Pharma Group Ltd – Key Employees 45
Mayne Pharma Group Ltd – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 48
Corporate Communications 48
Mar 09, 2017: Mayne Pharma appoints new Group CFO and Company Secretary 48
Jan 16, 2017: Mayne Pharma Announces Leadership Changes 49
Sep 21, 2016: Mayne Pharma Appoints New Director 50
Legal and Regulatory 51
Jul 29, 2016: Mayne Pharma Announces Settlement From Patent Infringement Case 51
Product Approvals 52
Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS 52
Clinical Trials 53
May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update 53
Oct 20, 2016: HedgePath Pharmaceuticals Announces Further Positive Interim Data in its Phase II(b) Cancer Trial 54
Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial 56
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Mayne Pharma Group Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 13
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 14
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 16
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 17
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 18
Mayne Pharma Enters into Distribution Agreement with IDT Australia 19
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 20
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 22
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 24
HedgePath Pharma Enters Into Licensing Agreement With Mayne Pharma 25
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 27
Mayne Pharma to Raise USD444.5 Million in Rights Offering of Shares 28
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 30
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 32
HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 33
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 34
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 35
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 36
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 37
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 39
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 40
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 41
Metrics Acquires Midlothian Labs From Hi-Tech Pharmacal 43
Mayne Pharma Group Ltd, Key Competitors 44
Mayne Pharma Group Ltd, Key Employees 45
Mayne Pharma Group Ltd, Other Locations 46
Mayne Pharma Group Ltd, Subsidiaries 46